======= EIF3E =======
== Gene Information ==
* **Official Symbol**: EIF3E
* **Official Name**: eukaryotic translation initiation factor 3 subunit E
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=3646|3646]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P60228|P60228]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=EIF3E&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20EIF3E|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/602210|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre- initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF- 3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). Required for nonsense-mediated mRNA decay (NMD); may act in conjunction with UPF2 to divert mRNAs from translation to the NMD pathway (PubMed:17468741). May interact with MCM7 and EPAS1 and regulate the proteasome-mediated degradation of these proteins (PubMed:17310990, PubMed:17324924). {ECO:0000255|HAMAP-Rule:MF_03004, ECO:0000269|PubMed:17310990, ECO:0000269|PubMed:17324924, ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:17581632, ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:27462815}.
|PCI|
|eIF3 N|
|eukaryotic translation initiation factor 3 complex, eIF3e|
|positive regulation of mRNA binding|
|positive regulation of RNA binding|
|regulation of mRNA binding|
|regulation of RNA binding|
|eukaryotic 48S preinitiation complex|
|formation of cytoplasmic translation initiation complex|
|eukaryotic translation initiation factor 3 complex|
|eukaryotic 43S preinitiation complex|
|negative regulation of translational initiation|
|cytoplasmic translational initiation|
|translation initiation factor activity|
|cytoplasmic translation|
|regulation of translational initiation|
|PML body|
|protein N-terminus binding|
|chromatin|
|nuclear-transcribed mRNA catabolic process, nonsense-mediated decay|
|positive regulation of translation|
|negative regulation of translation|
|translational initiation|
|negative regulation of cellular amide metabolic process|
|positive regulation of cellular amide metabolic process|
|positive regulation of binding|
|nuclear-transcribed mRNA catabolic process|
|mRNA catabolic process|
|ribonucleoprotein complex assembly|
|ribonucleoprotein complex subunit organization|
|RNA catabolic process|
|nuclear body|
|cadherin binding|
|regulation of translation|
|nucleobase-containing compound catabolic process|
|regulation of binding|
|translation|
|regulation of cellular amide metabolic process|
|peptide biosynthetic process|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|aromatic compound catabolic process|
|ribonucleoprotein complex biogenesis|
|organic cyclic compound catabolic process|
|posttranscriptional regulation of gene expression|
|amide biosynthetic process|
|peptide metabolic process|
|mRNA metabolic process|
|cellular amide metabolic process|
|cellular protein-containing complex assembly|
|cellular macromolecule catabolic process|
|negative regulation of cellular protein metabolic process|
|macromolecule catabolic process|
|negative regulation of protein metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|RNA binding|
|organonitrogen compound biosynthetic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|protein-containing complex assembly|
|positive regulation of cellular protein metabolic process|
|cellular nitrogen compound biosynthetic process|
|RNA metabolic process|
|positive regulation of protein metabolic process|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|macromolecule biosynthetic process|
|organic substance catabolic process|
|positive regulation of molecular function|
|cellular catabolic process|
|protein-containing complex subunit organization|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|membrane|
|gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp514|Phorbol-12-myristate-13-acetate 0.57μM R08 exp514]]|-1.71|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|1.74|
|[[:results:exp458|Bisphenol S 100μM R08 exp458]]|1.75|
|[[:results:exp245|UM0011500 5μM R05 exp245]]|1.75|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|1.76|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|1.77|
|[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|1.79|
|[[:results:exp139|Nicotinamide Riboside 100μM R03 exp139]]|1.81|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|1.81|
|[[:results:exp225|Celastrol 0.12μM R05 exp225]]|1.82|
|[[:results:exp18|Doxycycline 10μM R00 exp18]]|1.85|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|1.86|
|[[:results:exp241|QNZ 0.01μM R05 exp241]]|1.93|
|[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|1.95|
|[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|2.01|
|[[:results:exp182|IU1-47 25μM R04 exp182]]|2.01|
|[[:results:exp107|UMK57 0.6μM R03 exp107]]|2.05|
|[[:results:exp122|Golgicide-A 4μM R03 exp122]]|2.08|
|[[:results:exp151|SGC0946 7μM R03 exp151]]|2.14|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|2.21|
|[[:results:exp120|Dimethyl-Sulfoxide 1pc R03 exp120]]|2.22|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|2.23|
|[[:results:exp231|Epothilone-B 0.0015μM R05 exp231]]|2.24|
|[[:results:exp274|Citral 50μM R06 exp274]]|2.28|
|[[:results:exp146|Quinacrine 2.5μM R03 exp146]]|2.28|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|3.05|
^Gene^Correlation^
|[[:human genes:h:hgc6.3|HGC6.3]]|0.594|
Global Fraction of Cell Lines Where Essential: 707/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|26/28|
|blood|27/28|
|bone|23/26|
|breast|25/33|
|central nervous system|54/56|
|cervix|4/4|
|colorectal|17/17|
|esophagus|12/13|
|fibroblast|1/1|
|gastric|16/16|
|kidney|20/21|
|liver|20/20|
|lung|72/75|
|lymphocyte|16/16|
|ovary|26/26|
|pancreas|23/24|
|peripheral nervous system|16/16|
|plasma cell|14/15|
|prostate|1/1|
|skin|24/24|
|soft tissue|8/9|
|thyroid|2/2|
|upper aerodigestive|20/22|
|urinary tract|28/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 1156
* **Expression level (log2 read counts)**: 7.96
{{:chemogenomics:nalm6 dist.png?nolink |}}